Key facts
- It has raised $67.3M across 5 recorded rounds; the latest was Early Stage VC ($9.4M) in Jan 2025.
- Notable investors include Alan Richey, ACC Bioscience Incubator, David Shockley, Dr. John Butler, Jason Dorsey — 9 tracked in total.
- Nuclein has filed 10 Form Ds with the SEC since 2019, most recently Dec 2025 ($14.9M sold to 42 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Nuclein
Funding rounds
5 roundsAbout Nuclein
Developer of a rapid PCR testing system designed to deliver lab results at the point of care. The company's system offers a DASH Rapid PCR (Polymerase Chain Reaction) system of care instrument with test cartridges that can run a wide variety of sample types, enabling healthcare providers to make treatment decisions with minimal hands-on time.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 69
- Website
- nuclein.com/
- Ownership
- Privately Held (backing)
Nuclein doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuclein shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuclein in its N-PORT filings yet. We sweep new filings monthly.